Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 6 de 6
Skinmed ; 20(5): 387-389, 2022.
Article in English | MEDLINE | ID: covidwho-2093050


A 54-year-old man presented with worsening bilateral rashes on legs and arms 7 days after receiving his BNT162b2 mRNA COVID-19 (Pfizer) vaccine booster. He developed burning on his palms about 5 days after receiving the booster. On day 6, he observed significant edema on his fingers and palms in addition to thin erythematous papules on his forearms. On day 7, he developed edema on his bilateral dorsal feet, and thin erythematous plaques on his shins. He stated that the rashes were pruritic. He had no rashes following the first two doses of the Pfizer vaccine. He denied having any history of skin disease, autoimmune disease, or allergies. Physical examination revealed multiple thin erythematous papules coalescing into thin plaques on his flexor forearms, and thin erythematous plaques on his dorsal feet (Figure 1). Three 4-mm punch biopsies were performed on his left flexor forearm. The biopsies were carried out at papules present for different lengths of time. Papules at biopsy sites "A," "B," and "C" were present for approximately 24-36 hours, 12-18 hours, and 3-6 hours, respectively (Figure 1).

COVID-19 , Hypersensitivity, Delayed , Male , Humans , Middle Aged , COVID-19/complications , BNT162 Vaccine , Skin/pathology , Erythema/etiology , Erythema/pathology , Hypersensitivity, Delayed/diagnosis , Hypersensitivity, Delayed/etiology , Hypersensitivity, Delayed/pathology
J Cutan Pathol ; 49(1): 34-41, 2022 Jan.
Article in English | MEDLINE | ID: covidwho-1320386


BACKGROUND: As more people become vaccinated against the SARS-CoV-2 virus, reports of delayed cutaneous hypersensitivity reactions are beginning to emerge. METHODS: In this IRB-approved retrospective case series, biopsy specimens of potential cutaneous adverse reactions from the Pfizer-BioNTech or Moderna mRNA vaccine were identified and reviewed. Clinical information was obtained through the requisition form, referring clinician, or medical chart review. RESULTS: Twelve cases were included. Histopathological features from two injection-site reactions showed a mixed-cell infiltrate with eosinophils and a spongiotic dermatitis with eosinophils. Three biopsy specimens came from generalized eruptions that showed interface changes consistent with an exanthematous drug reaction. Three biopsy specimens revealed a predominantly spongiotic pattern, consistent with eczematous dermatitis. Small-vessel vascular injury was seen in two specimens, which were diagnosed as urticarial vasculitis and leukocytoclastic vasculitis, respectively. There were two cases of new-onset bullous pemphigoid supported by histopathological examination and direct immunofluorescence studies. Eosinophils were seen in 10 cases. CONCLUSIONS: Dermatopathologists should be aware of potential cutaneous adverse reactions to mRNA-based COVID-19 vaccines. Histopathological patterns include mixed-cell infiltrates, epidermal spongiosis, and interface changes. Eosinophils are a common finding but are not always present. Direct immunofluorescence studies may be helpful for immune-mediated cutaneous presentations such as vasculitis or bullous pemphigoid.

COVID-19 Vaccines/adverse effects , COVID-19/prevention & control , Drug-Related Side Effects and Adverse Reactions/pathology , Hypersensitivity, Delayed/pathology , 2019-nCoV Vaccine mRNA-1273/adverse effects , Adult , Aged , Aged, 80 and over , BNT162 Vaccine/adverse effects , Biopsy/methods , COVID-19/diagnosis , COVID-19/immunology , COVID-19/virology , Dermatitis/etiology , Dermatitis/pathology , Drug-Related Side Effects and Adverse Reactions/etiology , Eosinophils/pathology , Female , Fluorescent Antibody Technique, Direct/methods , Humans , Hypersensitivity, Delayed/etiology , Male , Middle Aged , Pemphigoid, Bullous/diagnosis , Pemphigoid, Bullous/pathology , Retrospective Studies , SARS-CoV-2/genetics , SARS-CoV-2/immunology , Skin/pathology , Vasculitis/chemically induced , Vasculitis/pathology
J Investig Allergol Clin Immunol ; 30(6): 385-399, 2020.
Article in English | MEDLINE | ID: covidwho-670233


The disease caused by the new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), ie, coronavirus disease 2019 (COVID-19), has become a global pandemic since it was first reported in Wuhan, China in December 2019. Its severe clinical manifestations, which often necessitate admission to intensive care units, and high mortality rate represent a therapeutic challenge for the medical community. To date, no drugs have been approved for its treatment, and various therapeutic options are being assayed to address the pathophysiological processes underlying the clinical manifestations experienced by patients. New and old drugs administered as monotherapy or in combination to immunologically compromised patients may favor the development of adverse drug reactions, including drug hypersensitivity reactions, which must be identified and managed accordingly. Given the lack of herd immunity and the high rate of viral contagion, new cases are expected to emerge in the coming months. Thus, the probability of more adverse reactions or even new clinical manifestations may increase in parallel. Allergists must receive updated information on these treatments, as well as on the management of possible drug hypersensitivity reactions.

Drug Hypersensitivity/diagnosis , Drug Hypersensitivity/etiology , Antiviral Agents/adverse effects , Antiviral Agents/therapeutic use , COVID-19/complications , COVID-19/immunology , COVID-19/pathology , Cytokines/antagonists & inhibitors , Diagnosis, Differential , Humans , Hypersensitivity, Delayed/diagnosis , Hypersensitivity, Delayed/etiology , Hypersensitivity, Immediate/diagnosis , Hypersensitivity, Immediate/etiology , Immunologic Factors/adverse effects , Immunologic Factors/therapeutic use , SARS-CoV-2